JP2017137289A5 - - Google Patents

Info

Publication number

JP2017137289A5

JP2017137289A5 JP2016152940A JP2016152940A JP2017137289A5 JP 2017137289 A5 JP2017137289 A5 JP 2017137289A5 JP 2016152940 A JP2016152940 A JP 2016152940A JP 2016152940 A JP2016152940 A JP 2016152940A JP 2017137289 A5 JP2017137289 A5 JP 2017137289A5

Authority

JP

Japan

Prior art keywords

risk

cystic fibrosis

medicament

patient

effective amount

Prior art date

2016-08-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims 66
• 201000003883 Cystic fibrosis Diseases 0.000 claims 62
• 230000002685 pulmonary effect Effects 0.000 claims 28
• 229940079593 drug Drugs 0.000 claims 26
• 239000000443 aerosol Substances 0.000 claims 21
• 239000003795 chemical substances by application Substances 0.000 claims 21
• 230000005713 exacerbation Effects 0.000 claims 20
• 210000004072 lung Anatomy 0.000 claims 17
• 241000589517 Pseudomonas aeruginosa Species 0.000 claims 16
• 150000001768 cations Chemical class 0.000 claims 15
• GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 13
• 208000032376 Lung infection Diseases 0.000 claims 13
• 229960003376 levofloxacin Drugs 0.000 claims 13
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
• 208000035143 Bacterial infection Diseases 0.000 claims 9
• 239000003242 anti bacterial agent Substances 0.000 claims 9
• 208000022362 bacterial infectious disease Diseases 0.000 claims 9
• GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 8
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 8
• 230000003115 biocidal effect Effects 0.000 claims 8
• 229910052749 magnesium Inorganic materials 0.000 claims 8
• 239000011777 magnesium Substances 0.000 claims 8
• 229960001699 ofloxacin Drugs 0.000 claims 8
• 229940124307 fluoroquinolone Drugs 0.000 claims 7
• 210000003296 saliva Anatomy 0.000 claims 7
• 229940088710 antibiotic agent Drugs 0.000 claims 6
• 239000008194 pharmaceutical composition Substances 0.000 claims 6
• 229910052742 iron Inorganic materials 0.000 claims 5
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 4
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 4
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
• 229910052791 calcium Inorganic materials 0.000 claims 4
• 239000011575 calcium Substances 0.000 claims 4
• 229910052802 copper Inorganic materials 0.000 claims 4
• 239000010949 copper Substances 0.000 claims 4
• 238000009472 formulation Methods 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 239000011701 zinc Substances 0.000 claims 4
• 229910052725 zinc Inorganic materials 0.000 claims 4
• 206010063659 Aversion Diseases 0.000 claims 3
• WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 3
• 229960003644 aztreonam Drugs 0.000 claims 3
• WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
• 206010057190 Respiratory tract infections Diseases 0.000 claims 2
• 230000001684 chronic effect Effects 0.000 claims 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
• 230000012953 feeding on blood of other organism Effects 0.000 claims 2
• 229960000707 tobramycin Drugs 0.000 claims 2
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
• KPPBAEVZLDHCOK-JHBYREIPSA-N (2s,3s)-3-[[(2z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonate;(2s)-2,6-diaminohexanoic acid Chemical group NCCCC[C@H](N)C(O)=O.O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 KPPBAEVZLDHCOK-JHBYREIPSA-N 0.000 claims 1
• XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
• 206010011224 Cough Diseases 0.000 claims 1
• 208000000059 Dyspnea Diseases 0.000 claims 1
• 206010013975 Dyspnoeas Diseases 0.000 claims 1
• 206010024264 Lethargy Diseases 0.000 claims 1
• 108010040201 Polymyxins Proteins 0.000 claims 1
• 241000589516 Pseudomonas Species 0.000 claims 1
• 206010040744 Sinus headache Diseases 0.000 claims 1
• 241000191940 Staphylococcus Species 0.000 claims 1
• 241000191967 Staphylococcus aureus Species 0.000 claims 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
• 229910052782 aluminium Inorganic materials 0.000 claims 1
• 229940126575 aminoglycoside Drugs 0.000 claims 1
• 230000004596 appetite loss Effects 0.000 claims 1
• 229950010471 aztreonam lysine Drugs 0.000 claims 1
• 230000036760 body temperature Effects 0.000 claims 1
• 229960003405 ciprofloxacin Drugs 0.000 claims 1
• 229960002549 enoxacin Drugs 0.000 claims 1
• IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims 1
• 230000029142 excretion Effects 0.000 claims 1
• 206010016256 fatigue Diseases 0.000 claims 1
• 125000001153 fluoro group Chemical group F* 0.000 claims 1
• 229960003923 gatifloxacin Drugs 0.000 claims 1
• 229960003170 gemifloxacin Drugs 0.000 claims 1
• ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims 1
• 229960002422 lomefloxacin Drugs 0.000 claims 1
• ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims 1
• 235000021266 loss of appetite Nutrition 0.000 claims 1
• 208000019017 loss of appetite Diseases 0.000 claims 1
• 230000004199 lung function Effects 0.000 claims 1
• 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
• 229960003702 moxifloxacin Drugs 0.000 claims 1
• FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
• 229960001180 norfloxacin Drugs 0.000 claims 1
• OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims 1
• 229960004236 pefloxacin Drugs 0.000 claims 1
• FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims 1
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
• 229960004954 sparfloxacin Drugs 0.000 claims 1
• DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims 1
• 208000016261 weight loss Diseases 0.000 claims 1
• 230000004580 weight loss Effects 0.000 claims 1